A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry

A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry

Abstract Background Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The Du...

Full description

Bibliographic Details
Main Authors: Etem Caliskan, Sigrid Sandner, Martin Misfeld, Jose Aramendi, Sacha P. Salzberg, Yeong-Hoon Choi, Vilas Satishchandran, Geeta Iyer, Louis P. Perrault, Andreas Böning, Maximilian Y. Emmert
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Cardiothoracic Surgery
Subjects:
Saphenous vein graft
Vein graft failure
Myocardial infarction
Coronary artery bypass grafting
Patency
Endothelial damage inhibitor
Online Access:http://link.springer.com/article/10.1186/s13019-019-1010-z

Internet

http://link.springer.com/article/10.1186/s13019-019-1010-z

Similar Items